Wird geladen...
Novel immunotherapy in metastatic renal cell carcinoma
Despite the rapid development of therapeutic modalities for metastatic renal cell carcinoma (mRCC) over the past decade to include a number of targeted antiangiogenic therapies and traditional immunotherapy, such as high-dose interleukin-2 and interferon-α, mRCC continues to be associated with poor...
Gespeichert in:
| Veröffentlicht in: | Investig Clin Urol |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
The Korean Urological Association
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5494344/ https://ncbi.nlm.nih.gov/pubmed/28681030 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4111/icu.2017.58.4.220 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|